Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Revenue (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Revenue for 13 consecutive years, with -$2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 100.73% year-over-year to -$2.1 million, compared with a TTM value of $722.3 million through Dec 2025, down 23.18%, and an annual FY2025 reading of -$7.9 million, down 100.84% over the prior year.
  • Revenue was -$2.1 million for Q4 2025 at Tandem Diabetes Care, down from $249.3 million in the prior quarter.
  • Across five years, Revenue topped out at $282.6 million in Q4 2024 and bottomed at -$2.1 million in Q4 2025.
  • Average Revenue over 5 years is $195.7 million, with a median of $198.5 million recorded in 2022.
  • The sharpest move saw Revenue soared 57.58% in 2021, then crashed 100.73% in 2025.
  • Year by year, Revenue stood at $210.0 million in 2021, then increased by 5.0% to $220.5 million in 2022, then decreased by 10.75% to $196.8 million in 2023, then soared by 43.62% to $282.6 million in 2024, then plummeted by 100.73% to -$2.1 million in 2025.
  • Business Quant data shows Revenue for TNDM at -$2.1 million in Q4 2025, $249.3 million in Q3 2025, and $240.7 million in Q2 2025.